From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations. Left unaddressed, they could undermine a trial or put patient safety at risk. In this paper, we discuss some of those issues and how sponsors can best address them.
Recent Insights » Whitepapers » Advances in Oncology Extend Lives, but Lead to New Safety Considerations for Sponsors and Investigators
Most Recent Flipbooks
Supporting Value Across the Regulatory Submission Continuum
Should You Be Adjudicating Your Clinical Endpoints?
Immunology Trials: Innovation Brings Hope, Fresh Challenges
Delivering CNS Trials Requires Specialized Clinical Knowledge
More Than Good Intentions: Diversity, Equity & Inclusion Requires a Program-Level, Strategic Framework
The Top 5 Benefits of Outsourcing Expert Committee Management to an Independent Provider
The Challenge of Overreporting: A Fresh Perspective from the FDA
In a recent webinar, Steven Beales, Senior VP, Scientific and Regulatory at WCG, facilitated a conversation with FDA leaders, discussing overreporting SUSARs and the impact on patient safety.
Tailored, Dedicated Support Expedites COVID-19 Vaccine Trial
Workforce Preparedness - A Proven Method to De-Risk Your Development
Reinventing Site Feasibility- Breaking Away From a Failed Status Quo
Q&A: A Fresh Perspective from the FDA on the Final IND Safety Reporting Rule
Big Challenges for Small Sponsors: Competition in Oncology Research
Don't Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise
Whitepaper - WCG Predict Analysis of MDD Study
Save the Data. Protect the Patients. Prepare for What Comes Next.
WCG CRCs Equip Sites With Tailored Support
Whitepaper - The Power of More Re-Imagining the Traditional Business Model for Oncology Clinical Research
WCG Virtual Study Training eBook
WCG Trends & Insights for 2021
Developing Annual Reports for Research Organizations